Revolution Medicines Zoldonrasib Phase 1 Data
Analysis based on 10 articles · First reported Apr 19, 2026 · Last updated Apr 19, 2026
The positive Phase 1 clinical data for zoldonrasib are expected to have a positive impact on Revolution Medicines' stock price and investor confidence, as it validates their drug development pipeline. This breakthrough could also signal a shift in the treatment landscape for KRAS G12D non-small cell lung cancer, potentially affecting other pharmaceutical companies in the oncology space.
Revolution Medicines announced updated positive Phase 1 clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). The results, presented at the American Association for Cancer Research Annual Meeting, showed a confirmed objective response rate of 52% and a disease control rate of 93% in a subset of patients. Zoldonrasib demonstrated a manageable safety profile, with most treatment-related adverse events being Grade 1. Jonathan Riess and Alan Sandler both highlighted the encouraging clinical activity and safety, supporting further development of zoldonrasib as a targeted therapy for RAS G12D-driven cancers, which currently lack approved targeted treatments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard